Skip to main content

Advertisement

SpringerLink
Log in

Perioperative management of antithrombotic therapy: a case-based narrative review

  • IM - REVIEW
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

The periprocedural management of patients who are receiving vitamin K antagonists, direct oral anticoagulants and antiplatelet therapy is a common and challenging clinical scenario as the decision to interrupt or continue these medications is anchored on patient and procedure-related risks for bleeding and thrombosis. Adding to the complexity of clinical management is the fact that anticoagulants have varied pharmacokinetic and pharmacodynamic properties and indications for clinical use. In many minimal-bleed-risk procedures, anticoagulants can be safely continued, without interruption, whereas in cases where anticoagulants cannot be safely continued, the timing of interruption and resumption, as well as the need for heparin bridging requires consideration. Perioperative antithrombotic management scenarios occur most often in patients with atrial fibrillation, mechanical heart valves, coronary stents, and cerebrovascular disease as such patients are likely to be prescribed anticoagulant and/or antiplatelet therapy. The objective of this case-based narrative review is to provide a practical evidence-based approach to the perioperative management of patients on anticoagulation and antiplatelet therapy. Four clinical scenarios will be provided: (1) managing patients in whom anticoagulants can be continued; (2) perioperative management of direct oral anticoagulants; (3) management of patients on dual antiplatelet therapy; and (4) anticoagulant management for emergency or urgent surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Availability of data and material

Not applicable.

Code availability

Not applicable.

References

  1. ClinCalc DrugStats Database. https://clincalc.com/DrugStats/. Accessed 8 Jun 2021

  2. Tafur A, Douketis J (2018) Perioperative management of anticoagulant and antiplatelet therapy. Heart 104:1461–1467. https://doi.org/10.1136/heartjnl-2016-310581

    Article  PubMed  Google Scholar 

  3. Dunn AS, Spyropoulos AC, Turpie AGG (2007) Bridging therapy in patients on long-term oral anticoagulants who require surgery: the prospective peri-operative enoxaparin cohort trial (PROSPECT). J Thromb Haemost 5:2211–2218. https://doi.org/10.1111/j.1538-7836.2007.02729.x

    Article  CAS  PubMed  Google Scholar 

  4. Spyropoulos AC, Brohi K, Caprini J et al (2019) Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: recommendations for standardized reporting of procedural/ surgical bleed risk and patient-specific. J Thromb Haemost 17:1966–1972. https://doi.org/10.1111/jth.14598

    Article  PubMed  Google Scholar 

  5. Douketis JD, Spyropoulos AC, Kaatz S et al (2015) Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 373:823–833. https://doi.org/10.1056/NEJMoa1501035

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kovacs MJ, Wells PS, Anderson DR et al (2021) Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. BMJ. https://doi.org/10.1136/BMJ.N1205

    Article  PubMed  PubMed Central  Google Scholar 

  7. Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104. https://doi.org/10.1056/NEJMoa1310907

    Article  CAS  PubMed  Google Scholar 

  8. Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891. https://doi.org/10.1056/NEJMoa1009638

    Article  CAS  PubMed  Google Scholar 

  9. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151. https://doi.org/10.1056/NEJMoa0905561

    Article  CAS  PubMed  Google Scholar 

  10. Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992. https://doi.org/10.1056/NEJMoa1107039

    Article  CAS  PubMed  Google Scholar 

  11. Bell BR, Spyropoulos AC, Douketis JD (2016) Perioperative Management of the Direct Oral Anticoagulants: A Case-Based Review. Hematol Oncol Clin North Am 30:1073–1084

    Article  Google Scholar 

  12. Douketis JD, Spyropoulos AC, Duncan J et al (2019) Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med 179:1469–1478. https://doi.org/10.1001/jamainternmed.2019.2431

    Article  PubMed  PubMed Central  Google Scholar 

  13. Birnie DH, Healey JS, Wells GA et al (2018) Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). Eur Heart J 39:3973–3979. https://doi.org/10.1093/eurheartj/ehy413

    Article  CAS  PubMed  Google Scholar 

  14. Banerjee S, Angiolillo DJ, Boden WE et al (2017) Use of antiplatelet therapy/DAPT for Post-PCI patients undergoing noncardiac surgery. J Am Coll Cardiol 69:1861–1870

    Article  Google Scholar 

  15. Douketis JD, Healey JS, Brueckmann M et al (2015) Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure: substudy of the RE-LY trial. Thromb Haemost 113:625–632. https://doi.org/10.1160/TH14-04-0305

    Article  PubMed  Google Scholar 

  16. Levy JH, Connors JM, Steiner ME et al (2020) Management of oral anticoagulants prior to emergency surgery or with major bleeding: a survey of perioperative practices in North America: communication from the scientific and standardization committees on perioperative and critical care haemostasis and thrombosis of the international society on thrombosis and haemostasis. Res Pract Thromb Haemost 4:562–568. https://doi.org/10.1002/rth2.12320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Jamula E, DOUKETIS JD, SCHULMAN S, (2008) Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide. J Thromb Haemost 6:1615–1621. https://doi.org/10.1111/J.1538-7836.2008.03080.X

    Article  CAS  PubMed  Google Scholar 

  18. Jamula E, Anderson J, Douketis JD (2009) Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis. Thromb Res 124:292–299. https://doi.org/10.1016/J.THROMRES.2009.01.007

    Article  CAS  PubMed  Google Scholar 

  19. Di BL, Burkhardt JD, Santangeli P et al (2014) Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients. Circulation 129:2638–2644. https://doi.org/10.1161/CIRCULATIONAHA.113.006426

    Article  CAS  Google Scholar 

  20. Müller P, Halbfass P, Szöllösi A et al (2016) Impact of periprocedural anticoagulation strategy on the incidence of new-onset silent cerebral events after radiofrequency catheter ablation of atrial fibrillation. J Interv Card Electrophysiol 46:203–211. https://doi.org/10.1007/s10840-016-0117-6

    Article  PubMed  Google Scholar 

  21. Finlay M, Sawhney V, Schilling R et al (2010) Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: a safe and cost-effective strategy. J Cardiovasc Electrophysiol 21:150–154. https://doi.org/10.1111/j.1540-8167.2009.01603.x

    Article  PubMed  Google Scholar 

  22. Brinkmeier-Theofanopoulou M, Tzamalis P, Wehrkamp-Richter S et al (2018) Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants. BMC Cardiovasc Disord. https://doi.org/10.1186/s12872-018-0804-6

    Article  PubMed  PubMed Central  Google Scholar 

  23. Birnie DH, Healey JS, Wells GA et al (2013) Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 368:2084–2093. https://doi.org/10.1056/NEJMoa1302946

    Article  CAS  PubMed  Google Scholar 

  24. Siegal D, Yudin J, Kaatz S et al (2012) Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 126:1630–1639

    Article  CAS  Google Scholar 

  25. Denas G, Marzot F, Offelli P et al (2008) (2008) Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases. J Thromb Thrombolysis 273(27):340–347. https://doi.org/10.1007/S11239-008-0211-4

    Article  Google Scholar 

  26. Woods K, Douketis JD, Kathirgamanathan K et al (2007) Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. J Thromb Thrombolysis 242(24):93–97. https://doi.org/10.1007/S11239-007-0022-Z

    Article  Google Scholar 

  27. Kaatz S, DOUKETIS JD, ZHOU H, et al (2010) Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost 8:884–890. https://doi.org/10.1111/J.1538-7836.2010.03781.X

    Article  CAS  PubMed  Google Scholar 

  28. Nogami A, Harada T, Sekiguchi Y et al (2019) Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Netw open 2:e191994. https://doi.org/10.1001/jamanetworkopen.2019.1994

    Article  PubMed  PubMed Central  Google Scholar 

  29. Reynolds MR, Allison JS, Natale A et al (2018) A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial. JACC Clin Electrophysiol 4:580–588. https://doi.org/10.1016/j.jacep.2017.11.005

    Article  PubMed  Google Scholar 

  30. Nakamura R, Okishige K, Shigeta T et al (2019) Clinical comparative study regarding interrupted and uninterrupted dabigatran therapy during perioperative periods of cryoballoon ablation for paroxysmal atrial fibrillation. J Cardiol 74:150–155. https://doi.org/10.1016/j.jjcc.2019.02.003

    Article  PubMed  Google Scholar 

  31. Takahashi N, Mukai Y, Kimura T et al (2019) Efficacy and safety of uninterrupted periprocedural edoxaban in patients undergoing catheter ablation for atrial fibrillation—the prospective KYU-RABLE study. Circ J 83:2017–2024. https://doi.org/10.1253/circj.CJ-19-0535

    Article  CAS  PubMed  Google Scholar 

  32. Brennan Y, Gu Y, Schifter M et al (2020) Dental extractions on direct oral anticoagulants vs. warfarin: the DENTST study. Res Pract Thromb Haemost 4:278–284. https://doi.org/10.1002/rth2.12307

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Essebag V, Proietti R, Birnie DH et al (2017) Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. Europace 19:1630–1636. https://doi.org/10.1093/europace/euw409

    Article  PubMed  Google Scholar 

  34. Rose DK, Bar B (2018) Direct oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents. J Stroke Cerebrovasc Dis 27:2049–2058

    Article  Google Scholar 

  35. Douketis J (2021) Perioperative anticoagulant use for surgery evaluation study part 2 pilot . In: Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT04192552?term=perioperative+bridging+anticoagulant&draw=2&rank=5. Accessed 28 Mar 2021

  36. Douketis JD, Syed S, Li N et al (2021) A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant. Res Pract Thromb Haemost 5:159–167. https://doi.org/10.1002/rth2.12430

    Article  PubMed  Google Scholar 

  37. Narouze S, Benzon HT, Provenzano D et al (2018) Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications (second edition): guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. https://doi.org/10.1097/AAP.0000000000000700

    Article  PubMed  PubMed Central  Google Scholar 

  38. Lewis SR, Pritchard MW, Schofield-Robinson OJ et al (2018) Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd012584.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  39. Myles PS, Smith JA, Forbes A et al (2016) Stopping vs. continuing aspirin before coronary artery surgery. N Engl J Med 374:728–737. https://doi.org/10.1056/NEJMoa1507688

    Article  CAS  PubMed  Google Scholar 

  40. Devereaux PJ, Mrkobrada M, Sessler DI et al (2014) Aspirin in patients undergoing noncardiac surgery. N Engl J Med 370:1494–1503. https://doi.org/10.1056/NEJMoa1401105

    Article  CAS  PubMed  Google Scholar 

  41. Sessler DI, Conen D, Leslie K et al (2020) One-year results of a factorial randomized trial of aspirin versus placebo and clonidine versus placebo in patients having noncardiac surgery. Anesthesiology 132:692–701. https://doi.org/10.1097/ALN.0000000000003158

    Article  PubMed  Google Scholar 

  42. Oscarsson A, Gupta A, redrikson M et al (2010) To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 104:305–312. https://doi.org/10.1093/bja/aeq003

    Article  CAS  PubMed  Google Scholar 

  43. Gherli R, Mariscalco G, Dalén M et al (2016) Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol 1:921–928. https://doi.org/10.1001/jamacardio.2016.3028

    Article  PubMed  Google Scholar 

  44. Smilowitz NR, Berger JS (2020) Perioperative cardiovascular risk assessment and management for noncardiac surgery: a review. JAMA - J Am Med Assoc 324:279–290

    Article  Google Scholar 

  45. Angiolillo DJ, Firstenberg MS, Price MJ et al (2012) Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 307:265–274. https://doi.org/10.1001/jama.2011.2002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Levy JH, Douketis J (2018) Weitz JI (2018) Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol 155(15):273–281. https://doi.org/10.1038/nrcardio.2017.223

    Article  CAS  Google Scholar 

  47. Leitch J, van Vlymen J (2017) Managing the perioperative patient on direct oral anticoagulants. Can J Anesth 64:656–672. https://doi.org/10.1007/s12630-017-0868-2

    Article  PubMed  Google Scholar 

  48. Levy JH (2016) Discontinuation and management of direct-acting anticoagulants for emergency procedures. Am J Emerg Med 34:14–18

    Article  Google Scholar 

  49. Levy JH, Faraoni D, Spring JL et al (2013) Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 118:1466–1474

    Article  CAS  Google Scholar 

  50. Lankiewicz MW, Hays J, Friedman KD et al (2006) Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 4:967–970. https://doi.org/10.1111/j.1538-7836.2006.01815.x

    Article  CAS  PubMed  Google Scholar 

  51. F D, W A, M C, (2006) Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 4:1853–1863. https://doi.org/10.1111/J.1538-7836.2006.01986.X

    Article  Google Scholar 

  52. Pollack CV, Reilly PA, van Ryn J et al (2017) Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. N Engl J Med 377:431–441. https://doi.org/10.1056/NEJMoa1707278

    Article  CAS  PubMed  Google Scholar 

  53. Goldstein JN, Refaai MA, Milling TJ et al (2015) Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 385:2077–2087. https://doi.org/10.1016/S0140-6736(14)61685-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Connolly SJ, Crowther M, Eikelboom JW et al (2019) Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 380:1326–1335. https://doi.org/10.1056/NEJMoa1814051

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Cuker A, Burnett A, Triller D et al (2019) Reversal of direct oral anticoagulants: guidance from the anticoagulation forum. Am J Hematol. https://doi.org/10.1002/ajh.25475

    Article  PubMed  Google Scholar 

  56. Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD (2016) Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost 14:875–885. https://doi.org/10.1111/jth.13305

    Article  CAS  PubMed  Google Scholar 

  57. Douketis JD, Spyropoulos AC, Spencer FA et al (2012) Perioperative management of antithrombotic therapy. Antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e326S-e350S. https://doi.org/10.1378/chest.11-2298

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

No funds or grants were received for this paper.

Author information

Authors and Affiliations

  1. Department of Medicine, St. Joseph’s Healthcare Hamilton, McMaster University, F-544, 50 Charlton Ave East, Hamilton, ON, L8N 4A6, Canada

    Andrew Tiger Chen, Matthew Patel & James Demetrios Douketis

Authors
  1. Andrew Tiger Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James Demetrios Douketis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James Demetrios Douketis.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest.

Ethics approval

Not applicable.

Human and animal rights

There was no involvement of patients or animal subjects in this work and research ethics board involvement was deemed to be unncessary.

Consent to Participate

Not applicable.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, A.T., Patel, M. & Douketis, J.D. Perioperative management of antithrombotic therapy: a case-based narrative review. Intern Emerg Med 17, 25–35 (2022). https://doi.org/10.1007/s11739-021-02866-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-021-02866-x

Keywords

Search

Navigation